Cochrane Ireland

Nov 21, 2024 | systematicreviewsjournal.biomedcentral.com | Canadian Association |Cochrane Ireland

As a community of scholars and practitioners of evidence synthesis and evidence synthesis technology, including developers of evidence synthesis technology tools and authors of evidence synthesis guidelines, we have developed through discussion and debate a set of recommendations that aim to enable the successful and responsible realisation of the potential benefits of ML-prioritised screening. These recommendations (see overview in Fig.

Aug 2, 2024 | jclinepi.com | Cochrane Ireland

This paper is only available as a PDF. To read, Please Download here. To read this article in full you will need to make a paymentSubscribe to Journal of Clinical EpidemiologyArticle infoIn Press Journal Pre-ProofDeclaration of interests☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Mar 11, 2024 | trialsjournal.biomedcentral.com | Cochrane Ireland

There is a significant amount of avoidable waste in producing and reporting evidence from randomised trials [1]. Some of this waste stems from uncertainty about how best to undertake specific trial processes: recruitment and retention of trial participants, for instance, are essential to nearly all trials but remain a persistent challenge [2, 3]. Despite this, the evidence available to support trialists’ decisions about recruitment and retention is minimal [4, 5].

Dec 6, 2023 | thelancet.com | Cochrane Ireland

Search strategy and selection criteriaWe developed a comprehensive search strategy following the PCC (Population, Content, Context) and using keywords such as ‘SEAR countries’, ‘Operational research’, ‘Monitoring and evaluation’, ‘Assessment’, ‘Emergency preparedness’, ‘Emergency response’, ‘Risk communications’, ‘Outbreak investigation’, ‘Outbreak response’, ‘Risk Management’, ‘Public health emergency’, ‘Outbreak’, ‘Pandemic’, ‘Endemic’ etc.